Results 211 to 220 of about 131,697 (294)
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source
Potential mechanisms within the digital stress-management intervention <i>StressProffen</i> for cancer survivors: a qualitative study post randomized controlled trial. [PDF]
Varsi C +5 more
europepmc +1 more source
An approach to automatic answering for English reading comprehension tests
Phuong Bui, Hieu Chi Tran, H. T. Duong
openalex +2 more sources
Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed +10 more
wiley +1 more source
When a model gives you mixed signals: cognitive effects and visual behavior. [PDF]
Abbad-Andaloussi A +4 more
europepmc +1 more source
Improving Comprehension Of Capital Sentencing Instructions: A Bias Reduction Approach
Charles W. Otto
openalex +1 more source
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto +13 more
wiley +1 more source

